"Pathways": A hope-enhancing intervention for patients undergoing treatment for advanced lung cancer.

Autor: McLouth LE; Department of Behavioral Science, Center for Health Equity Transformation, University of Kentucky College of Medicine, Lexington, Kentucky, USA.; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA., Shelton BJ; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.; Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA., Bursac V; Department of Behavioral Science, Center for Health Equity Transformation, University of Kentucky College of Medicine, Lexington, Kentucky, USA., Burris JL; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.; Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, Kentucky, USA., Cheavens JS; Department of Psychology, The Ohio State University, Columbus, Ohio, USA., Weyman K; Medical College of Wisconsin Affiliated Hospitals, Madison, Wisconsin, USA., Peterman AH; Department of Psychological Science, University of North Carolina-Charlotte, Charlotte, North Carolina, USA., Corum L; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA., Studts JL; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Arnold SM; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.; Division of Medical Oncology, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Jazyk: angličtina
Zdroj: Psycho-oncology [Psychooncology] 2024 Mar; Vol. 33 (3), pp. e6316.
DOI: 10.1002/pon.6316
Abstrakt: Objective: Observational data suggest hope is associated with the quality of life and survival of people with cancer. This trial examined the feasibility, acceptability, and preliminary outcomes of "Pathways," a hope intervention for people in treatment for advanced lung cancer.
Methods: Between 2020 and 2022, we conducted a single-arm trial of Pathways among participants who were 3-12 weeks into systemic treatment. Pathways consisted of two individual sessions delivered during infusions and three phone calls in which participants discussed their values, goals, and goal strategies with a nurse or occupational therapist. Participants completed standardized measures of hope and goal interference pre- and post-intervention. Feasibility was defined as ≥60% of eligible patients enrolling, ≥70% of participants completing three or more sessions, ≥70% of participants completing post-assessments, and mean acceptability ratings ≥7 out of 10 on intervention relevance, helpfulness, and convenience. Linear regression fixed effects models with covariates modeled pre-post changes in complete case analysis and multiple imputation models.
Results: Fifty two participants enrolled: female (59.6%), non-Hispanic White (84.6%), rural (75.0%), and with low educational attainment (51.9% high school degree or less). Except for enrollment (54%), feasibility and acceptability markers were surpassed (77% adherence, 77% retention, acceptability ratings ≥8/10). There was moderate improvement in hope and goal interference from pre-to post-intervention (d = 0.51, p < 0.05 for hope; d = -0.70, p < 0.005 for goal interference).
Conclusions: Strong feasibility, acceptability, and patient-reported outcome data suggest Pathways is a promising intervention to increase hope and reduce cancer-related goal interference during advanced lung cancer treatment.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: